DRUG solubility(Cilostazol is considered a potential anti-platelets drug exhibiting also antithrombotic effects. Unfortunately, cilostazol shows low oral bioavailability due to its low aqueous solubility. Nanofibers are a promising new class of drug delivery materials that can improve...
The oral LD50 of cilostazol is >5.0 g/kg in mice and rats and >2.0 g/kg in dogs.|IDENTIFICATION AND USE: Cilostazol forms colorless, needle-like crystals. As the oral drug Pletal, it is indicated for the reduction of symptoms of intermittent claudication. HUMAN EXPOSURE AND TOXICITY: The...
Brand name: Pletal Drug class: Platelet-aggregation InhibitorsMedically reviewed by Drugs.com on Apr 10, 2024. Written by ASHP.Introduction Uses Dosage Warnings Interactions Stability Warning Contraindicated in patients with CHF of any severity. Decreased survival observed in patients with NYHA class II...
of administration.In addition,The cilostazol is classified as a drug of class II by the classification system and the solubility of biopharmaceutical drug as a factor that interferes with the rate and extent of absorptionWhat can affect bioavailability.This patent describes the process of obtaining ...
Food effect on meal administration time of pharmacokinetic profile of cilostazol, a BCS class II drug.doi:10.1080/00498254.2019.1602746Masateru MiyakeYoshikazu OkaTadashi MukaiTaylor & Francis
Micronization is one technique, employed for dissolution enhancement of cilostazol, a BCS class II drug. However, the obtained micronized drug possesses poor flowability. The aim of this study was to improve the dissolution rate and flow properties of cilostazol by crystal engineering, using habit ...
Drug available to treat Diabetic Nephropathy (DN) faces bioavailability issues related to solubility and absorption of drugs. Cilostazol (CLT) is a BCS class II\ndrug that is poorly water-soluble which affects its therapeutic efficacy. CLT reduces reactive oxygen species (ROS) increased in DN. ...
Cilostazol is a poorly soluble drug belonging to class II of the biopharmaceutics classification system. To improve the solubility and in turn bioavailability of cilostazol, a lipid based nanoemulsifying cilostazol was developed.Self nanoemulsifying system comprising of Capmul MCM (oily solubilizer), ...
Of the 12 patients with hepatic impairment examined in this study, 10 had mild impairment (Child-Pugh class A) and 2 had moderate impairment (Child-Pugh class B). Main Outcome Measures: Blood and urine were collected up to 144 hours after drug administration. Pharmacokinetics were determined ...
In this review, we discuss the mechanism of action of cilostazol and evaluate the efficacy and safety of the drug based on the results of clinical trials. Furthermore, we comprehensively explore the role of cilostazol in the prevention and treatment of atherosclerosis. 2. Limitations of Aspirin ...